Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11979504 | 0.76 | ADORA2A (0.35) | ADORA2AADORA1CYP1A2LRRK2 | |
| SCHEMBL25018708 | 0.76 | ADORA2A (0.33) | ADORA2AADORA1ACHE | |
| SCHEMBL22057944 | 0.74 | ADORA2A (0.34) | ADORA2AADORA1ACHE | |
| SCHEMBL12302868 | 0.73 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL22021178 | 0.73 | ADORA2A (0.41) | ADORA2AADORA1 | |
| SCHEMBL11060138 | 0.73 | ADORA2A (0.33) | ADORA2AADORA1ACHE | |
| SCHEMBL25019153 | 0.72 | ACHE (0.32) | ADORA2AADORA1ACHECYP1A2LRRK2 | |
| SCHEMBL17454480 | 0.72 | LRRK2 (0.39) | ADORA2AADORA1ACHECYP1A2LRRK2 | |
| SCHEMBL19224382 | 0.71 | ADORA2A (0.33) | ADORA2AADORA1ACHE | |
| SCHEMBL24848624 | 0.71 | PIK3CD (0.31) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023096928-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ADORA2A 744/4885ADORA1 826/4885ACHE 1176/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | ADORA2A 744/4885ADORA1 826/4885ACHE 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.